RxDoctor Payments Data

Jeffrey Drood, MD

Cardiovascular Disease · McMinnville, ORNPI 1558419770

Payments from drug & device makers

$594in general payments, 2019–2025

Across 21 payments — averaging $28.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$224
  • Abbott$111
  • AstraZeneca$45
  • Boston Scientific$44
  • Johnson & Johnson$36
  • Preventice Services, LLC$29
  • plus $106 from 6 others

What the payments were for

  • Food & beverage$594100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$594 in reported general payments places this provider in the 35th percentile of 198 cardiovascular disease providers in Oregon.

See all cardiovascular disease providers in Oregon

Medicare billing

Part B allowed, 2024
$90,046
Medicare patients
655
Services billed
1,493

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban199$240,602
EntrestoSacubitril/Valsartan28$45,045
JardianceEmpagliflozin13$22,505
Repatha SureclickEvolocumab13$18,602
XareltoRivaroxaban12$17,690
Metoprolol Succinate154$2,827
Rosuvastatin Calcium122$2,492
Atorvastatin Calcium123$1,561
Losartan Potassium119$1,466
Carvedilol87$967
ClopidogrelClopidogrel Bisulfate64$795
Amlodipine Besylate100$735
Potassium Chloride23$559
Lisinopril60$487
Hydrochlorothiazide55$462

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$22$22,50513 claims
Johnson & JohnsonXarelto$36$17,69012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 198 cardiovascular disease providers in Oregon.

Other cardiovascular disease in McMinnville

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →